Reacción a "Reactions: EMA authorises Hipra's Spanish vaccine against covid-19"

It is always good news when a new vaccine is approved to add to the existing ones in the fight against covid-19, and even better news if the vaccine is manufactured in Spain, with all that this implies.  

It is a vaccine that uses a classic recombinant protein technology (containing the S protein of the original variant and the Beta variant) adjuvanted.  

But I am sorry to cool down a bit the expectations that have been raised with Hipra and the minister's statements in this regard. Firstly, it has yet to prove that it is a better vaccine than existing vaccines; there is insufficient evidence to make such a claim. Secondly, Hipra uses a technology (recombinant protein) that does not allow for rapid adaptation to changes in the virus. In this respect, mRNA technology is always more flexible and faster, and this is precisely one of the advantages of mRNA technology over existing technologies. 

I am convinced that it will produce very good results. In particular, this vaccine, which uses a different platform, should be indicated for people who have not responded efficiently to the initial regimen with an mRNA vaccine, and thus benefit from the advantages of a heterologous combination, which has proved so successful so far.